BB Biotech
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (July 2012) |
 | |
| Company type | Aktiengesellschaft |
|---|---|
| SIX: BION, FWB: BBZA | |
| Industry | Investments |
| Founded | Schaffhausen, Switzerland (9 November 1993) |
| Headquarters | Küsnacht, Switzerland |
Key people | Erich Hunziker (Chairman) |
| Products | Investment in biotechnology companies |
| CHF 391 million (2012)[1] | |
 (CHF 367.8 million) (2012)[2] | |
| Total assets | CHF 1.3763 billion (2012)[1] |
| Total equity | CHF 1.234 billion (2012)[1] |
| Website | www.bbbiotech.ch |
BB Biotech AG (Bank am Bellevue) is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and since 2000 on the Italian Borsa Italiana.[3]
At of March 31, 2015 the six largest holdings in the BB Biotech portfolio were (in order of value): a 10.7% stake in Celgene; 9.5% of Isis Pharmaceuticals; , 9.1% of Incyte, 7.3% of Gilead Sciences; 7.3% of Actelion; 4.6% of Agios Pharmaceuticals.
Company Figures[4]
| (figures in millions CHF) | 2012 | 2013 | 2014 |
|---|---|---|---|
| revenues | 145,25 | 184,76 | 221,25 |
| operating profit | 368,60 | 932,22 | 1.469,31 |
| Profit | 367,83 | 931,83 | 1.470,14 |
| Equity | 1.234,01 | 2.118,87 | 3.492,53 |
| Market capitalization | 3.480 |
References
- ^ a b c "Annual Report 2012" (PDF). BB Biotech. Retrieved 29 November 2013.[permanent dead link]
- ^ "Annual Report 2010" (PDF). BB Biotech. Retrieved 13 March 2011.[permanent dead link]
- ^ "BB Biotech - Facts & Figures". BB Biotech. Retrieved 2013-11-28.
- ^ finanzen.net Retrieved 1st of January 2016.
External links
 | This Swiss corporation or company article is a stub. You can help Wikipedia by expanding it. |